2 secret growth stocks I’d buy and hold for 10 years

These two growth stocks should continue to produce results no matter what the future holds.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Companies that provide a critical business service for other firms often make the best investments as their revenues are sticky. In other words, itthey’res unlikely to disappear overnight as clients can’t switch to other offerings easily.

This is why I believe Alfa Financial Software (LSE: ALFA) and Microgen (LSE: MCGN) are perfect buy-and-forget growth stocks to hold for the next 10 years.

Profits double 

Today Alfa reported its first annual results since its IPO last year, showcasing its strengths. The company, which provides “mission critical software for the asset finance industry,” announced today that revenue for 2017 rose 20% to £88m, or 9% year-on-year to £86m at constant currency. Pre-tax profit surged to £34m, double last year’s reported figure of £17m.

However, it seems that the market is displeased with management’s growth outlook. Due to currency fluctuations, growth is expected to slow in 2018. Specifically, alongside today’s numbers, CEO Andrew Denton said a backdrop of a weakening dollar means the board expects to report low double-digit top line growth on a budget rate, or mid double-digit growth on a constant currency basis. It seems investors have also been disappointed by the lack of a dividend announcement for the year.

Still, despite this downbeat outlook, the long-term opportunity ahead of Alfa, and its peer Microgen, is tremendous. For example, Alfa estimates its addressable software market is over $3bn, compared to its current revenue run-rate of £88m ($123m).

City analysts are expecting the firm’s earnings per share to jump 15% for 2018 after last year’s surge in profitability. And as long as Alfa continues to provide a professional service to clients, I believe earnings can continue to grow at a double-digit rate for the foreseeable future.

Growth through acquisitions 

Bolt-on acquisitions are another tactic Alfa can use to boost growth. Microgen has chosen this route, using organic cash flow to buy up growth. In August of last year, the firm announced the acquisition of RevStream Inc, a California-based provider of revenue management enterprise software expanding its portfolio of mission-critical software businesses.

Following this deal, and others like it, the firm’s adjusted earnings per share increased by 39% to 17.1p for 2017, smashing City estimates of 15.2p. After this strong performance, it looks as if analysts are behind the curve with the company as they were expecting earnings per share of 18.3p for 2018. Considering 2017’s outperformance, I wouldn’t be surprised if analysts revised their forecasts for future growth substantially higher in the months ahead.

Unfortunately, the one problem with both Microgen and Alfa is that the shares currently command a high valuation. Shares in Microgen are trading at a forward P/E of 27.8 and Alfa is trading at a forward P/E of just under 40. While high, these valuations reflect the bespoke and sticky nature of these businesses’ revenue streams and future growth potential.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves owns no share mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Here’s how I’d target passive income from FTSE 250 stocks right now

Dividend stocks aren't the only ones we can use to try to build up some long-term income. No, I like…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

If I put £10k in this FTSE 100 stock, it could pay me a £1,800 second income over the next 2 years

A FTSE 100 stock is carrying a mammoth 10% dividend yield and this writer reckons it could contribute towards an…

Read more »

Investing Articles

2 UK shares I’d sell in May… if I owned them

Stephen Wright would be willing to part with a couple of UK shares – but only because others look like…

Read more »

Investing Articles

2 FTSE 250 shares investors should consider for a £1,260 passive income in 2024

Investing a lump sum in these FTSE 250 shares could yield a four-figure dividend income this year. Are they too…

Read more »

A pastel colored growing graph with rising rocket.
Investing Articles

This FTSE share has grown its decade annually for over 30 years. Can it continue?

Christopher Ruane looks at a FTSE 100 share that has raised its dividend annually for decades. He likes the business,…

Read more »

Elevated view over city of London skyline
Investing Articles

Few UK shares grew their dividend by 90% in 4 years. This one did!

Among UK shares, few have the recent track record of annual dividend increases to match this one. Our writer likes…

Read more »

Investing Articles

This FTSE 250 share yields 9.9%. Time to buy?

Christopher Ruane weighs some pros and cons of buying a FTSE 250 share for his portfolio that currently offers a…

Read more »

Affectionate Asian senior mother and daughter using smartphone together at home, smiling joyfully
Investing Articles

As the NatWest share price closes in on a new 5-year high, will it soon be too late to buy?

The NatWest share price has climbed strongly so far in 2024, as the whole bank sector has been enjoying a…

Read more »